Complement factor H: a biomarker for progression of cutaneous squamous cell carcinoma.

J Invest Dermatol

Department of Dermatology, University of Turku and Turku University Hospital, Turku, Finland; MediCity Research Laboratory, University of Turku, Turku, Finland. Electronic address:

Published: February 2014

The incidence of cutaneous squamous cell carcinoma (cSCC) is increasing globally. We have studied the expression of complement system components in cSCC. Expression profiling of cSCC cell lines (n=8) and normal human epidermal keratinocytes (n=5) with Affymetrix and quantitative real-time PCR (qPCR) revealed upregulation of complement factor H (CFH) and factor H-like protein-1 (FHL-1) in cSCC cell lines. The expression of CFH and FHL-1 mRNAs was also significantly higher in cSCC tumors (n=6) than in normal skin (n=11). Analysis of CFH and FHL-1 expression in vivo in invasive cSCCs (n=65), in situ cSCCs (n=38), and premalignant lesions (actinic keratoses, n=37) by immunohistochemistry showed that they were specifically expressed by tumor cells in cSCCs and the staining intensity was stronger in cSCCs than in in situ cSCCs and actinic keratoses. The expression of CFH by cSCC cells was upregulated by IFN-γ and the basal CFH and FHL-1 expression was dependent on extracellular signal-regulated kinase (ERK)1/2 and p38 signaling. Knockdown of CFH and FHL-1 expression inhibited proliferation and migration of cSCC cells and inhibited basal ERK1/2 activation. These results provide evidence for a role of CFH and FHL-1 in cSCC progression and identify them as progression markers and potential therapeutic targets in SCCs of skin.

Download full-text PDF

Source
http://dx.doi.org/10.1038/jid.2013.346DOI Listing

Publication Analysis

Top Keywords

cfh fhl-1
20
fhl-1 expression
12
complement factor
8
cutaneous squamous
8
squamous cell
8
cell carcinoma
8
cscc
8
cscc cell
8
cell lines
8
fhl-1 cscc
8

Similar Publications

Article Synopsis
  • The study investigates the role of complement dysregulation in age-related macular degeneration (AMD) and a specific variant of complement factor H (CFH) in early-onset macular drusen (EOMD).
  • Researchers identified a new CFH variant in a family with EOMD and used patient-derived stem cells to analyze the effects of CFH and factor H-like protein 1 (FHL-1) on complement activity.
  • The CFH variant led to reduced expression of CFH and FHL-1 and increased complement activation in retinal cells, providing evidence that CFH deficiencies contribute to EOMD development.
View Article and Find Full Text PDF

Purpose: Complement dysregulation in the eye has been implicated in the pathogenesis of age-related macular degeneration (AMD), and genetic variants of complement factor H (CFH) are strongly associated with AMD risk. We therefore aimed to untangle the role of CFH and its splice variant, factor H-like 1 (FHL-1), in ocular complement regulation derived from local versus circulating sources. We assessed the therapeutic efficacy of adeno-associated viruses (AAVs) expressing human FHL-1 and a truncated version of CFH (tCFH), which retains the functional N- and C-terminal ends of the CFH protein, in restoring the alternative complement pathway in Cfh-/- mouse eyes and plasma.

View Article and Find Full Text PDF

Factor H is a pivotal complement regulatory protein that is preferentially produced by the liver and circulates in high concentrations in serum. There has been an increasing interest in the extrahepatic production of complement factors, including by cells of the immune system, since this contributes to non-canonical functions of local complement activation and regulation. Here we investigated the production and regulation of factor H and its splice variant factor H-like protein 1 (FHL-1) by human myeloid cells.

View Article and Find Full Text PDF
Article Synopsis
  • - After years of setbacks, complement-targeted therapies are now recognized as effective treatments for various diseases, leading to renewed interest in their potential benefits.
  • - The discussion highlights the need for improved diagnostics alongside these therapies, emphasizing the role of complement biomarkers, particularly the human factor H (FH) protein family, in assessing disease risk and treatment responses.
  • - The review aims to synthesize current research on circulating levels of FH proteins across different diseases and outlines crucial next steps for integrating these findings into clinical practice.
View Article and Find Full Text PDF

Besides being a key effector arm of innate immunity, a plethora of non-canonical functions of complement has recently been emerging. Factor H (FH), the main regulator of the alternative pathway of complement activation, has been reported to bind to various immune cells and regulate their functions, beyond its role in modulating complement activation. In this study we investigated the effect of FH, its alternative splice product FH-like protein 1 (FHL-1), the FH-related (FHR) proteins FHR-1 and FHR-5, and the recently developed artificial complement inhibitor mini-FH, on two key innate immune cells, monocytes and neutrophilic granulocytes.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!